Menu Close

Articles on aducanumab

Displaying all articles

An illustration of amyloid plaques within the human brain, characteristic features of Alzheimer’s. By 2060, approximately 14 million Americans are expected to have the disease. Kateryna Kon/Science Photo Library via Getty Images

The FDA approved a new drug to treat Alzheimer’s, but Medicare won’t always pay for it – a doctor explains what researchers know about Biogen’s Aduhelm

Although Medicare has agreed to pay for Aduhelm, its coverage comes with restrictions.
Alzheimer’s disease is characterized by progressive memory loss, spatial disorientation and many other cognitive and behavioural disorders that ultimately lead to a state of total dependence. (Shutterstock)

FDA approval of controversial Alzheimer’s drug could delay discovery of more promising treatments

The new drug is based on the idea that a build-up of amyloid in the brain leads to the disease. But that hypothesis has been under scrutiny lately.
Do the benefits of approving a drug before confirming it works outweigh the potential costs? monkeybusinessimages/iStock via Getty Images Plus

The FDA’s big gamble on the new Alzheimer’s drug

The FDA approved Alzheimer’s disease drug aducanumab despite minimal evidence of its efficacy. Whether this decision ultimately hurts or helps patients depends on data researchers don’t yet have.

Top contributors

More